Common Stock, $0.0001 par value per share
- Symbol
- EVMN
- Exchange
- NYSE
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
Evommune, Inc.
EVMNNYSEEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 1, 2026, Evommune, Inc. issued a press release titled "Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress". A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.…
Company context
Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.
Current securities
Registered securities in this filing
Evommune, Inc. · 8-K · Filed 2026-10-01
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On October 1, 2026, Evommune, Inc. issued a press release titled "Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress". A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Filed exhibits (1)
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress - Presentation highlights EVO301’s clear therapeutic signal, favorable safety and tolerability profile, and reinforces IL‑18 inhibition as a novel, clinically relevant approach to treating atopic dermatitis - Biomarker analyses confirm robust Th2 pathway modulation, as well as broad anti‑inflammatory activity across multiple inflammatory pathways (Th1, Th17/22) - Plan to initiate subcutaneous Phase 2b dose‑ranging trial in mid‑2027 PALO ALTO, Calif. & NEW YORK (October 1, 2026) - Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today shared additional data from its Phase 2a proof-of-concept trial of EVO301 in adults with moderate-to-severe atopic dermatitis (AD) during a late-breaking oral presentation at the European Academy of Dermatology and Venereology (EADV) 2026 Congress in Vienna, Austria. EVO301 is a long‑acting injectable fusion protein designed to selectively inhibit overa…
Open exhibit ↗